Slingshot Insights | Idra Overview

IDRA Overview

Upcoming Projects (IDRA)

Don’t see a project related to the company you care about? Create your own!

Expired Projects (IDRA)

Comparing results metastatic melanoma in PD-1 progressing patients. IOVA, IDRA, ONCS, REPL, CMPI all have results at this year's SITC in this 2L PD-1 refractory melanoma population. We ask an expert to compare trial designs and results
Tickers: IOVA, IDRA, ONCS, REPL, CMPI
Execute By: Jan 29, 2021

Upcoming & Overdue Catalysts (IDRA)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (IDRA)

Idera (IDRA) Agrees to Global License Agreement with Vivelix Pharma to Develop IMO-9200 for Non-Malignant Gastrointestinal (GI) Disorders
Tickers: IDRA, Vivelix Pharmaceuticacls
Occurred on: Nov 28, 2016
Phase 1/2 data of IMO-8400 for patients with DLBCL who harbor the MYD88 L265P mutation due 2016
Ticker: IDRA
Occurred on: Sep 26, 2016
Data from the IMO-2125 melanoma trial expected in the second half of 2016
Ticker: IDRA
Occurred on: Aug 02, 2016

Strategic Initiatives (IDRA)

Don’t see a strategic initiative related to the company you care about? Create your own!